Moxifloxacin inhibits cytokine-induced MAP kinase and NF-κB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line

Abstract

Moxifloxacin inhibits intracellular signalling, iNOS expression and NO secretion in a lung epithelial cell line. Future studies may uncover a primary site of quinolone immunomodulation, either upstream or at the cell membrane. Eventually, this quinolone might become an important therapy for inflammatory lung diseases.